Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 102, Issue 15, 2005, Pages 5507-5512

  Tate, Sarah K ^a   Depondt, Chantal ^a,b   Sisodiya, Sanjay M ^b,c   Cavalleri, Gianpiero L ^a   Schorge, Stephanie ^b   Soranzo, Nicole ^a   Thom, Maria ^b   Sen, Arjune ^b   Shorvon, Simon D ^b   Sander, Josemir W ^b,c   Wood, Nicholas W ^b   Goldstein, David B ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

^d DUKE UNIVERSITY   (United States)

Author keywords

Association study; Epilepsy; Pharmacogenetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 2C9; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG TARGETING; EPILEPSY; EXON; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; RNA SPLICING;

ADOLESCENT; ADULT; AGED; ALLELES; AMINO ACID SEQUENCE; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BRAIN; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPILEPSY; EXONS; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; INFANT; INTRONS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PHENYTOIN; POLYMORPHISM, GENETIC; SODIUM CHANNELS;

EID: 20244368950     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0407346102     Document Type: Article

References (32)

1. Kupfer, A. & Preisig, R. (1984) Eur. J. Clin. Pharmacol. 26, 753-759.
2. Ceulemans, B. F., Claes, L. R. & Lagae, L. G. (2004) Pediatr. Neurol. 30, 236-243.
3. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) Proc. Natl. Acad. Sci. USA 97, 3473-3478.
4. Soranzo, N., Cavalleri, G. L., Weale, M. E., Wood, N. W., Depondt, C., Marguerie, R., Sisodiya, S. M. & Goldstein, D. B. (2004) Genome Res. 14, 1333-1344.
5. Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W. & Sisodiya, S. M. (2003) N. Engl. J. Med. 348, 1442-1448.
6. Kerb, R., Aynacioglu, A. S., Brockmoller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgartner, C., Ongen, H. Z., et al. (2001) Pharmacogenomics J. 1, 204-210.
7. Wilkinson, G. R. (1996) J. Pharmacokinet. Biopharm. 24, 475-490.
8. Ozdemir, V., Kalowa, W., Tang, B. K., Paterson, A. D., Walker, S. E., Endrenyi, L. & Kashuba, A. D. (2000) Pharmacogenetics 10, 373-388.
9. Hsieh, K. P., Lin, Y. Y., Cheng, C. L., Lai, M. L., Lin, M. S., Siest, J. P. & Huang, J. D. (2001) Drug Metab. Dispos. 29, 268-273.
10. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., et al. (2001) Pharmacogenetics 11, 447-458.
11. Lamba, J. K., Lin, Y. S., Schuetz, E. G. & Thummel, K. E. (2002) Adv. Drug Deliv. Rev. 54, 1271-1294.
12. Ball, S. E., Scatina, J., Kao, J., Perron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., Warner, N., et al. (1999) Clin. Pharmacol. Ther. 66, 288-294.
13. Potschka, H., Fedrowitz, M. & Loscher, W. (2001) Neuroreport 12, 3557-3560.
14. Weale, M. E., Depondt, C., Macdonald, S. J., Smith, A., Lai, P. S., Shorvon, S. D., Wood, N. W. & Goldstein, D. B. (2003) Am. J. Hum. Genet. 73, 551-565.
15. Andrew, T., Hart, D. J., Snieder, H., de Lange, M., Spector, T. D. & MacGregor, A. J. (2001) Twin Res. 4, 464-477.
16. Schaid, D. J., Rowland, C. M., Tines, D. E., Jacobson, R. M. & Poland, G. A. (2002) Am. J. Hum. Genet. 70, 425-434.
17. Copley, R. R. (2004) Trends Genet. 20, 171-176.
18. Tan, J., Liu, Z., Nomura, Y., Goldin, A. L. & Dong, K. (2002) J. Neurosci. 22, 5300-5309.
19. Gastaldi, M., Bartolomei, F., Massacrier, A., Planells, R., Robaglia-Schlupp, A. & Cau, P. (1997) Brain Res. Mol. Brain Res. 44, 179-190.
20. Freedman, M. L., Reich, D., Penney, K. L., McDonald, G. J., Mignault, A. A., Patterson, N., Gabriel, S. B., Topol, E. J., Smoller, J. W., Pato, C. N., et al. (2004) Nat. Genet. 36, 388-393.
21. Reich, D. E. & Goldstein, D. B. (2001) Genet. Epidemiol. 20, 4-16.
22. Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. (2003) Nat. Rev. Genet. 4, 937-947.
23. Plummer, N. W. & Meisler, M. H. (1999) Ceramics 57, 323-331.
24. Shorvon, S. D., Fish, D. R., Perucca, E., Dodson, W. E. & Avanzini, G. (2004) The Treatment of Epilepsy (Blackwell, Oxford).
25. Ingelman-Sundberg, M. (2004) Trends Pharmacol. Sci. 25, 193-200.
26. Rettie, A. E., Haining, R. L., Bajpai, M. & Levy, R. H. (1999) Epilepsy Res. 35, 253-255.
27. Aynacioglu, A. S., Brockmoller, J., Bauer, S., Sachse, C., Guzelbey, P., Ongen, Z., Nacak, M. & Roots, I. (1999) Br. J. Clin. Pharmacol. 48, 409-415.
28. Gotoh, O. (1992) J. Biol. Chem. 267, 83-90.
29. Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M. & Chiba, K. (2000) Pharmacogenetics 10, 95-104.
30. Odani, A., Hashimoto, Y., Otsuki, Y., Uwai, Y., Hattori, H., Furusho, K. & Inui, K. (1997) Clin. Pharmacol. Ther. 62, 287-292.
31. Mamiya, K., Ieiri, I., Shimamoto, J., Yukawa, E., Imai, J., Ninomiya, H., Yamada, H., Otsubo, K., Higuchi, S. & Tashiro, N. (1998) Epilepsia 39, 1317-1323.
32. Lee, C. R., Goldstein, J. A. & Pieper, J. A. (2002) Pharmacogenetics 12, 251-263.